3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Lung Neoplasms
20
Carcinoma, Hepatocellular
18
Breast Neoplasms
16
Small Cell Lung Carcinoma
14
Urinary Bladder Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
7
Liver Neoplasms
7
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Renal Cell
5
Carcinoma
5
Biliary Tract Neoplasms
5
Stomach Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Neoplasms by Site
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Uterine Cervical Neoplasms
2
Turcot syndrome
2
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Interventions
Radiosurgery
23
Temozolomide
9
Radiotherapy
8
pembrolizumab
6
Cyclophosphamide
6
abemaciclib
5
Nivolumab
5
Radiation
4
Mental Status and Dementia Tests
4
Bevacizumab
4
trastuzumab deruxtecan
3
trametinib
3
pertuzumab
3
osimertinib
3
entrectinib
3
Surveys and Questionnaires
3
Proton Therapy
3
Magnetic Resonance Spectroscopy
3
Lomustine
3
Ipilimumab
3
Immunoglobulin G
3
Disulfides
3
Cisplatin
3
tucatinib
2
encorafenib
2
binimetinib
2
Vincristine
2
Trastuzumab
2
Surgical Procedures, Operative
2
Spermine Synthase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Brain Neoplasms
×
durvalumab
×
Clear all
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled